TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1

MLA

Christina Funk, et al. “TheraVision: Engineering Platform Technology for the Development of Oncolytic Viruses Based on Herpes Simplex Virus Type 1.” Molecular Therapy: Oncology, vol. 32, no. 1, Mar. 2024. EBSCOhost, https://doi.org/10.1016/j.omton.2024.200784.

APA

Christina Funk, Nadja Uhlig, Zsolt Ruzsics, Florentin Baur, Matthias Peindl, Sarah Nietzer, Karina Epting, Gabriele Vacun, Gudrun Dandekar, Catherine Botteron, Christian Werno, Thomas Grunwald, & Susanne M. Bailer. (2024). TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1. Molecular Therapy: Oncology, 32(1). https://doi.org/10.1016/j.omton.2024.200784

Chicago

Christina Funk, Nadja Uhlig, Zsolt Ruzsics, Florentin Baur, Matthias Peindl, Sarah Nietzer, Karina Epting, et al. 2024. “TheraVision: Engineering Platform Technology for the Development of Oncolytic Viruses Based on Herpes Simplex Virus Type 1.” Molecular Therapy: Oncology 32 (1). doi:10.1016/j.omton.2024.200784.